These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34849707)

  • 1. Use of rapid cardiac magnetic resonance imaging to guide chelation therapy in patients with transfusion-dependent thalassaemia in India: UMIMI study.
    Medina KM; Abdel-Gadir A; Ganga K; Ojha V; Pratap S; Boubertakh R; McGrath L; Augusto JB; Rikowski A; Mughal N; Khanna VK; Seth T; Sharma S; Mahajan A; Bansal RK; Srivastava P; Mahajan H; Mahajan V; Walker J; Seldon T; Ako E; Moon JC; Walker JM
    Eur Heart J Qual Care Clin Outcomes; 2022 May; 8(3):289-297. PubMed ID: 34849707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low prevalence of cardiac siderosis in heavily iron loaded Egyptian thalassemia major patients.
    El Beshlawy A; El Tagui M; Hamdy M; El Ghamrawy M; Azim KA; Salem D; Said F; Samir A; St Pierre T; Pennell DJ
    Ann Hematol; 2014 Mar; 93(3):375-9. PubMed ID: 23949317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of cardiac iron overload by optimising iron chelation therapy in transfusion dependent thalassaemia using cardiac T2* MRI: a quality improvement project from Pakistan.
    Hussain S; Hoodbhoy Z; Ali F; Hasan E; Alvi N; Hussain A; Ishrat K; Ur Rahman Z; Qamruddin A; Parvin A; Hasan BS
    Arch Dis Child; 2020 Nov; 105(11):1041-1048. PubMed ID: 32994214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Importance of Cardiac T2* Magnetic Resonance Imaging for Monitoring Cardiac Siderosis in Thalassemia Major Patients.
    Chaosuwannakit N; Makarawate P; Wanitpongpun C
    Tomography; 2021 Apr; 7(2):130-138. PubMed ID: 33919601
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
    Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD
    Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac T2* MRI assessment in patients with thalassaemia major and its effect on the preference of chelation therapy.
    Akcay A; Salcioglu Z; Oztarhan K; Tugcu D; Aydogan G; Ayaz NA; Bornaun H; Sen HS; Akici F; Akdana B
    Int J Hematol; 2014 Jun; 99(6):706-13. PubMed ID: 24719246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of heart iron with preserved patterns of iron store by CMR-guided chelation therapy.
    Meloni A; Positano V; Ruffo GB; Spasiano A; D'Ascola DG; Peluso A; Keilberg P; Restaino G; Valeri G; Renne S; Midiri M; Pepe A
    Eur Heart J Cardiovasc Imaging; 2015 Mar; 16(3):325-34. PubMed ID: 25246505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion-dependent thalassemia: A randomized double-blind placebo-controlled trial.
    Gupta V; Kumar I; Raj V; Aggarwal P; Agrawal V
    Pediatr Blood Cancer; 2022 Jun; 69(6):e29564. PubMed ID: 35092347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD004450. PubMed ID: 23963793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.
    Karakas Z; Yilmaz Y; Bayramoglu Z; Karaman S; Aydogdu S; Karagenc AO; Tugcu D; Dursun M
    Radiol Med; 2018 Aug; 123(8):572-576. PubMed ID: 29663188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac magnetic resonance in transfusion dependent thalassaemia: assessment of iron load and relationship to left ventricular ejection fraction.
    Chouliaras GL; Kattamis A; Berdoukas V; Gotsis ED; Mavrogeni S; Ladis V
    Br J Haematol; 2010 Nov; 151(4):397-401. PubMed ID: 20813008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of global strain values of myocardium in beta-thalassemia major patients with iron load using specific feature tracking in cardiac magnetic resonance imaging.
    Rezaeian N; Mohtasham MA; Khaleel AJ; Parnianfard N; Kasani K; Golshan R
    Int J Cardiovasc Imaging; 2020 Jul; 36(7):1343-1349. PubMed ID: 32346846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between left ventricular strain and cardiac iron load in beta-thalassaemia major: a cardiac magnetic resonance study.
    Alis D; Asmakutlu O; Topel C; Sahin AA; Karaarslan E
    Acta Cardiol; 2022 Feb; 77(1):71-80. PubMed ID: 33685353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of desferrioxamine chelation versus no therapy in patients with non transfusion-dependent thalassaemia: a multicenter prospective comparison from the MIOT network.
    Ricchi P; Meloni A; Pistoia L; Spasiano A; Spiga A; Allò M; Gamberini MR; Lisi R; Campisi S; Peluso A; Missere M; Renne S; Mangione M; Positano V; Pepe A
    Ann Hematol; 2018 Oct; 97(10):1925-1932. PubMed ID: 29926157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart rate variability in β-thalassaemia major with or without cardiac siderosis.
    Alp A; Ozdogan O; Guloglu CC; Turker M; Atabay B
    Cardiol Young; 2014 Apr; 24(2):263-7. PubMed ID: 23402458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal monitoring of cardiac siderosis using cardiovascular magnetic resonance T2* in patients with thalassemia major on various chelation regimens: a 6-year study.
    Ambati SR; Randolph RE; Mennitt K; Kleinert DA; Weinsaft JW; Giardina PJ
    Am J Hematol; 2013 Aug; 88(8):652-6. PubMed ID: 23640778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of cardiac complications for thalassemia major in the widespread cardiac magnetic resonance era: a prospective multicentre study by a multi-parametric approach.
    Pepe A; Meloni A; Rossi G; Midiri M; Missere M; Valeri G; Sorrentino F; D'Ascola DG; Spasiano A; Filosa A; Cuccia L; Dello Iacono N; Forni G; Caruso V; Maggio A; Pitrolo L; Peluso A; De Marchi D; Positano V; Wood JC
    Eur Heart J Cardiovasc Imaging; 2018 Mar; 19(3):299-309. PubMed ID: 28200076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac t2*.
    Ha SY; Mok AS; Chu WC; Rasalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
    Hemoglobin; 2011; 35(3):199-205. PubMed ID: 21599432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI.
    Ruffo GB; Borsellino Z; Cuccia L; Marocco MR; Gagliardotto F; Tarantino R
    Clin Drug Investig; 2010; 30(4):267-73. PubMed ID: 20225910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.